Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin - Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...

AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...